Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients
- PMID: 17991198
- DOI: 10.1111/j.1525-139X.2007.00336.x
Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients
Abstract
The homocysteine (Hcy) theory states that total homocysteine (tHcy) is a risk factor for atherosclerosis. Chronic kidney disease (CKD) is one of the most frequent causes of hyperhomocysteinemia in the presence of high prevalence of cardiovascular disease (CVD). However, there is not yet any conclusive answer to the question whether Hcy may contribute to, or predict, cardiovascular events or mortality in CKD patients or whether it is just an innocent bystander biologically related to other potential risk factors for CVD. Moreover, tHcy levels in CKD are influenced by several commonly occurring confounding factors, such as inflammation and protein-energy wasting (PEW). These factors are also associated with morbidity and mortality and altogether this may explain why Hcy does not show up as a cardiovascular risk but in fact is reversely associated with clinical outcome. Thorough evaluation of such reverse association may not necessarily imply that the principles of Hcy being a contributor to vascular pathophysiology are different in CKD patients but rather indicate that other superimposed factors, such as PEW and inflammation, are more important. These confounders contribute significantly to the unacceptably high mortality rate in this patient population and may require nutritional and anti-inflammatory interventions to improve clinical outcome. So far, the results of recent folic acid intervention trials do not support the use of folic acid supplementation for lowering tHcy and improving survival in CKD patients. Although we are still waiting for the results from several ongoing controlled randomized trials in this area, future studies are needed to evaluate if thiol-exchange agents, besides folic acid, as part of a future multifactorial intervention regime targeting inflammation, PEW, oxidative stress as well as hyperhomocysteinemia may decrease CVD risk in this high-risk patient population.
Similar articles
-
Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.Clin Chim Acta. 2008 Sep;395(1-2):106-10. doi: 10.1016/j.cca.2008.05.018. Epub 2008 Jun 27. Clin Chim Acta. 2008. PMID: 18565329
-
Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S89-95. doi: 10.1053/ajkd.2003.50093. Am J Kidney Dis. 2003. PMID: 12612961 Review.
-
Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.Am J Kidney Dis. 2009 Sep;54(3):478-89. doi: 10.1053/j.ajkd.2009.01.266. Epub 2009 Apr 8. Am J Kidney Dis. 2009. PMID: 19359080
-
Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.Am J Kidney Dis. 2006 Jan;47(1):60-71. doi: 10.1053/j.ajkd.2005.09.032. Am J Kidney Dis. 2006. PMID: 16377386
-
Homocysteine, B-vitamins and CVD.Proc Nutr Soc. 2008 May;67(2):232-7. doi: 10.1017/S0029665108007076. Proc Nutr Soc. 2008. PMID: 18412997 Review.
Cited by
-
Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders.Curr Cardiol Rev. 2023;19(4):e090223213539. doi: 10.2174/1573403X19666230209111854. Curr Cardiol Rev. 2023. PMID: 36757031 Free PMC article.
-
Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?Cardiorenal Med. 2017 Oct;7(4):255-266. doi: 10.1159/000471813. Epub 2017 Jun 21. Cardiorenal Med. 2017. PMID: 29118764 Free PMC article. Review.
-
Interventions for lowering plasma homocysteine levels in dialysis patients.Cochrane Database Syst Rev. 2016 May 31;2016(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Cochrane Database Syst Rev. 2016. PMID: 27243372 Free PMC article.
-
Association between homocysteinemia and mortality in CKD: A propensity-score matched analysis using NHANES-National Death Index.Medicine (Baltimore). 2022 Sep 9;101(36):e30334. doi: 10.1097/MD.0000000000030334. Medicine (Baltimore). 2022. PMID: 36086712 Free PMC article.
-
High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease.Nutrients. 2016 Oct 20;8(10):645. doi: 10.3390/nu8100645. Nutrients. 2016. PMID: 27775590 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical